FLT3 binds type II TKI

Stable Identifier
R-HSA-9695831
Type
Reaction [binding]
Species
Homo sapiens
Compartment
plasma membrane, cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
FLT3 binds type II TKI
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
FLT3 can be bound and inhibited by class II tyrosine kinase inhibitors including sunitinib, sorafenib and others. Type II inhibitors bind to the inactive conformation of the kinase and prevent its activation (reviewed in Larrosa-Garcia and Baer, 2017; Lim et al, 2017; Klug et al, 2018).
Literature References
PubMed ID Title Journal Year
28576946 FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Baer, MR, Larrosa-Garcia, M

Mol. Cancer Ther. 2017
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Heinrich, MC, Kent, JD, Klug, LR

Pharmacol. Ther. 2018
28851395 Molecular targeting in acute myeloid leukemia

Dubielecka, PM, Lim, SH, Raghunathan, VM

J Transl Med 2017
Participants
Input
Output
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-07-15)
Cite Us!